A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.
Rezūm therapy significantly improved symptoms, urinary flow, and quality of life in men across a wide range of prostate sizes, data show.
The procedure is now performed in one-third of all surgeries for benign prostatic hyperplasia, a study found.
Data on whether 5-ARIs increase the risk of prostate cancer-specific mortality have been mixed.
Prostatic artery embolization is a minimally invasive surgical technique that involves selective cannulation of the prostatic arteries.
Bothersome or not, lower urinary tract symptoms increase mortality risk in men.
The likelihood of conversion from HoLEP to an open procedure to treat benign prostatic hyperplasia increases along with prostate size.
Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.
At prostate cancer diagnosis, clinical T stage was significantly higher among 5-ARI users compared with nonusers.
Laser enucleation of the prostate accounts for less than 5% of all BPH procedures performed in the US.